This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allergan's Botox Gets FDA Nod for Forehead Line Treatment
by Zacks Equity Research
Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.
Amgen Enters Into an Immuno-Oncology Partnership With CytomX
by Zacks Equity Research
Amgen (AMGN) has entered into a strategic immuno-oncology collaboration with CytomX to jointly develop a T-cell engaging bispecific probody.
Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen
by Zacks Equity Research
Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen
Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up
by Zacks Equity Research
Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617.
Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy
by Zacks Equity Research
Mallinckrodt plc (MNK) entered into a licensing agreement with NeuroproteXeon for the development and commercialization of the latter's investigational, pharmaceutical-grade xenon gas for inhalation therapy.
Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA
by Zacks Equity Research
Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.
5 Top ROE Stocks to Buy as Markets Snub Geopolitical Threats
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern
Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.
Lilly (LLY) Makes Leadership Changes to Executive Positions
by Zacks Equity Research
Eli Lilly and Company (LLY) makes some executive appointments for various departments.
Is Biogen Inc. (BIIB) a Great Stock for Value Investors?
by Zacks Equity Research
Lets put Biogen Inc.(BIIB) stock into this equation and find out if it is a good choice for value-oriented investors right now.
AbbVie Submits NDA for Endometriosis Candidate to the FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.
Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study
by Zacks Equity Research
Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents.
Biogen Alzheimer's Drug Shows Promise in Long-Term Study
by Zacks Equity Research
Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.
Company News For August 29, 2017
by Zacks Equity Research
Companies in the news are: EXPE,BIIB,GILD,KITE,JNJ
Biogen's Humira Biosimilar Imraldi Gets Approval in EU
by Zacks Equity Research
Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.
What You See, and What You Get: The Neurology of Perception
by Kevin Cook
While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.
The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix
PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings surpass expectations. Revenues also significantly increase year over year, thanks to a rise in fair value of the Depomed royalty asset.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.
Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line
by Zacks Equity Research
Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.
Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed
by Zacks Equity Research
Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.
Biogen (BIIB) Tops Q2 Earnings and Revenue
by Zacks Equity Research
Biogen (BIIB) reported better-than expected earnings in the second quarter of 2017 with revenue beating estimates.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.